Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis

doi:10.1038/srep00201

Sci Rep. 2011; 1: 201.

Published online 2011 December 19. doi: 10.1038/srep00201

PMCID: PMC3242013

Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis

Tej K. Pareek,¹ Abdelmadjid Belkadi,² Sashi Kesavapany,³ Anita Zaremba,² Sook L. Loh,³ Lianhua Bai,² Mark L. Cohen,⁴ Colin Meyer,⁵ Karen T. Liby,⁶ Robert H. Miller,² Michael B. Sporn,⁶ and John J. Letterio^a¹

¹Department of Pediatrics/Division of Pediatric Hematology-Oncology, University Hospitals Case Medical Center and The Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH44106

²Centers for Stem Cells and Regenerative Medicine, Translational Neuroscience, Department of Neurosciences, Case Western Reserve University, School of Medicine, Ohio 44106, Cleveland

³Department of Biochemistry, Neurobiology Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597

⁴Department of Pathology, Case Western Reserve University, OH 44106

⁵Reata Pharmaceuticals Inc., Irving, TX 75063

⁶Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755

^aEmail: John.Letterio/at/UHhospitals.org

Received October 27, 2011; Accepted November 18, 2011.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareALike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Abstract

Inflammatory cytokines and endogenous anti-oxidants are variables affecting disease progression in multiple sclerosis (MS). Here we demonstrate the dual capacity of triterpenoids to simultaneously repress production of IL-17 and other pro-inflammatory mediators while exerting neuroprotective effects directly through Nrf2-dependent induction of anti-oxidant genes. Derivatives of the natural triterpene oleanolic acid, namely CDDO-trifluoroethyl-amide (CDDO-TFEA), completely suppressed disease in a murine model of MS, experimental autoimmune encephalomyelitis (EAE), by inhibiting Th1 and Th17 mRNA and cytokine production. Encephalitogenic T cells recovered from treated mice were hypo-responsive to myelin antigen and failed to adoptively transfer the disease. Microarray analyses showed significant suppression of pro-inflammatory transcripts with concomitant induction of anti-inflammatory genes including Ptgds and Hsd11b1. Finally, triterpenoids induced oligodendrocyte maturation in vitro and enhanced myelin repair in an LPC-induced non-inflammatory model of demyelination in vivo. These results demonstrate the unique potential of triterpenoid derivatives for the treatment of neuroinflammatory disorders such as MS.

The dynamic regulation of cytoprotective genes in response to inflammatory mediators contributes to the relapsing-remitting nature of multiple sclerosis (MS)¹. In murine models of MS, initiation of disease requires induction of a Th17 T cell response with disease manifestations ultimately resulting from activated macrophages which phagocytose myelin and contribute to degeneration of myelin sheaths, oligodendrocytes and axons². Activated monocytes and macrophages produce inflammatory mediators, including nitric oxide and reactive oxygen species (ROS), which contribute to the development and progression of the disease³^,4. Generation of ROS in brain parenchyma contributes to lesion persistence by mediating oligodendroglial damage and axonal injury⁵^,6, and reduced serum levels of antioxidants have been observed in patients with MS⁷.

The central nervous system is endowed with several protective mechanisms consisting of enzymatic and non-enzymatic antioxidants whose expression is regulated through the transcription factor nuclear factor-E2-related factor (Nrf2) and the antioxidant response element (ARE). In humans with MS, enhanced expression of Nrf2/ARE-regulated antioxidants in the brain is indicative of the response to oxidative stress, and in mice disruption of Nrf2 gene expression (Nrf2^−/− mice) leads to exacerbation of clinical and pathological symptoms of experimental autoimmune encephalomyelitis (EAE)⁸. Nrf2^−/− mice are also hypersensitive to LPS-induced neuroinflammation⁹ and Nrf2 is reported to be involved in maintaining CNS myelin¹⁰. To date, over 200 Nrf2/ARE-driven genes involved in detoxification and antioxidant defense have been identified, out of which superoxide dismutases (SOD), glutathione peroxidases, GPxs¹¹, catalases⁴^,12^,13, and hemeoxygenases-1 (Hmox-1)¹⁴^,15 are all modulated during MS.

The families of natural and synthetic triterpenoids have recently emerged as potent regulators of the Nrf2/ARE pathway. Triterpenoids represent a broad category of molecules ubiquitously present in the plant kingdom¹⁶^,17, and used widely in Asian medicine (usually in the form of herbal extracts)¹⁸. Among these natural triterpenoids, the natural pentacyclic triterpene oleanolic acid (OA) displays numerous biological properties with therapeutic potential¹⁸^,19. Both OA and herbal extracts containing OA are known for their immunomodulatory properties²⁰ and have been shown to reduce clinical pathology associated with neuroinflammation and EAE²¹^,22.

Oleanolic acid has served as the platform for synthesis of several novel triterpenoids, including 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me) which is currently in Phase III clinical trials in patients with diabetic nephropathy²³^,24. In preclinical studies, CDDO-methyl amide (CDDO-MA) was shown to exert neuroprotective effects through potent activation of the Nrf2/ARE pathway and is neuroprotective in preclinical model systems, including a transgenic model of Alzheimer's disease²⁵. Further derivatization of CDDO to yield an imidazolide (CDDO-Im), an ethyl amide, (CDDO-EA), or a trifluoroethyl amide (CDDO-TFEA), resulted in significantly increased biological activity²⁶, and enhanced capacity to cross the blood brain barrier (BBB)²⁷.

In this study we reveal the mechanisms mediating neuroprotective effects of three CDDO derivatives CDDO-Me, CDDO-EA and CDDO-TFEA in the treatment of EAE. Daily systemic administration of these compounds alone significantly alleviates the clinical symptoms of disease. We show that CDDO-TFEA not only induces Nrf2 expression and signaling both in affected CNS tissue as well as in peripheral lymphocytes, but also leads to global suppression of inflammatory response genes in mice with EAE and suppression of disease associated cytokines, particularly interleukin-17 (IL-17). Lastly, CDDO-TFEA protects against non-inflammatory lysophosphatidyl choline (LPC)-induced demyelination suggesting a direct action of this molecule on myelin preservation and repair. These results reveal the potency and unique mechanisms through which novel synthetic triterpenoids, specifically CDDO derivatives, suppress disease progression in the setting of inflammatory neurodegenerative disease.

Results

CDDO derivatives promote complete resolution of EAE

To investigate the efficacy of selected synthetic triterpenoids (Fig. 1A), mice were immunized with either MOG 35–55 (C57BL/6 mice) or PLP (139–151) (Balb/C mice) and received systemic administration of either CDDO-Me, CDDO-EA, or CDDO-TFEA after the onset of disease. Administration of triterpenoids every alternate day for 10 days significantly improved survival (Fig 1B) and led to complete abrogation of clinical symptoms within the first two weeks of treatment, regardless of disease score at the onset of treatment (Fig. 1 C). Recrudescence of disease symptoms was significantly delayed after treatment with CDDO-TFEA, when compared to CDDO-Me (Fig. S1-A) and CDDO-EA (Fig. S1-B). Re-exposure of these mice to the same molecule resulted in complete suppression of clinical symptoms in all treatment groups. The severity of symptoms at disease relapse was low and survival was greater than 90% for mice treated with either the ethyl-amide or trifluoroethylamide derivatives. The beneficial effects of CDDO-TFEA were reproducible in the remitting relapsing model of PLP (139–151)-induced EAE (Fig. 1D). The effect of these small molecules on EAE disease progression may involve a combination of suppressive activity on the peripheral immune system and direct neuroprotective effects in the CNS. The former is supported by our observation that lymphocytes collected from mice immunized with MOG (35–55) and subsequently exposed to CDDO-TFEA completely failed to adoptively transfer disease to untreated mice (Fig. S2).

Figure 1

Systemic administration of CDDO derivatives ameliorates the severity of EAE.

CDDO-TFEA attenuates CNS inflammation and demyelination in mice with EAE

To assess the effects of CDDO-TFEA and other derivatives on EAE-associated CNS pathology, lumbar spinal cord and brain stem were obtained from mice either at the peak of disease severity or at a point when disease scores approached baseline. Independent histological analysis of brain stem (Fig. S3) and spinal cord demonstrated reduced inflammation (Fig. 2A–C & 2M) and minimal demyelination (Fig. 2D–F & 2N), in CDDO-TFEA-treated animals when compared with the untreated control group. There was a significant reduction in the number of F4/80 (macrophage and microglia; Fig. 2G–I) and myeloperoxidase (neutrophil, Fig. 2J–L) positive cells in the lumbar spinal cord of mice treated with CDDO-TFEA. These data support a conclusion that suppression of immune and inflammatory cell populations is one mechanism underlying the response to synthetic triterpenoids in EAE.

Figure 2

Decreased inflammation and preservation of myelin content after CDDO-TFEA treatment.

Treatment with CDDO-TFEA diminishes inflammatory cytokine levels

Our laboratory and others have shown direct suppressive effects of triterpenoids on immune cell activation and on receptor-mediated activation of signaling intermediates including Stat3 and NFκB²⁸^,29. To determine whether triterpenoid suppression of CNS infiltration by immune cells in mice with EAE was linked to suppression of the immune response in the periphery, we first analyzed serum and supernatants of cultured peripheral blood lymphocytes harvested from mice with EAE and re-stimulated ex vivo in the presence or absence of CDDO-TFEA (Fig. 3A–G). A significant reduction in Th1 and Th17 cytokines (i.e. IL6, IL17, IFNγ, TNFα and GMCSF) was observed while IL-2 production was not altered significantly. Lymphocytes collected from spleen and inguinal lymph nodes of mice 21 days after MOG (35–55) injection secreted several cytokines when restimulated with MOG (35–55) peptide ex vivo, but production of IL2, IL4, IL6, IL17, TNF-α, IFN-γ and GMCSF was significantly lower in lymphocytes harvested from mice treated with CDDO-TFEA. When these data were normalized for cell proliferation (to account for effects of CDDO-TFEA on cell growth) the differences in IL17 and GMCSF production remained highly significant.

Figure 3

CDDO-TFEA treatment suppressed production of key inflammatory cytokines by lymphocytes during EAE.

CDDO-TFEA suppresses antigen-specific lymphocyte responses and modulates Hmox-1 and iNOS protein expression

The data presented thus far suggest that triterpenoids may suppress EAE through direct effects on immune cell activation and function. We hypothesized that CDDO-TFEA might impair development of an antigen-specific memory response to MOG (35–55) through direct suppression of T cell activation or cytokine driven proliferative expansion. Here we show that CDDO-TFEA treatment significantly inhibited the responses to CD3/CD28 and IL7 both alone and in combination (Fig. S4). Interleukein-7 (IL7) is a non-redundant cytokine essential for T cell survival and development and T cell memory³⁰. Patients suffering with MS have a higher level of IL7 and IL7R-alpha in the cerebrospinal fluid compared with patients suffering from other non-inflammatory neurological disorders³¹. CDDO-TFEA significantly suppressed IL-7 stimulated in vitro proliferation of both quiescent and activated T cells isolated from spleen and lymph nodes of mice immunized with MOG (Fig. S4). We assessed the ex vivo responsiveness of lymphocytes isolated from lymph nodes and spleen of either a) control mice, b) MOG(35–55)-immunized mice with symptoms of EAE or c) MOG(35–55)-immunized mice following treatment with CDDO-TFEA. Lymphocytes derived from lymph nodes of symptomatic mice restimulated with MOG (35–55) in vitro had a more than 5-fold greater proliferative response relative to control lymphocytes, but this response was significantly diminished in cultures of lymphocytes isolated from mice treated with CDDO-TFEA in vivo. In either case, the in vitro treatment of these cells with CDDO-TFEA completely blocked proliferation in response to MOG (35–55) (Fig. 4A). These data demonstrate a direct suppression of the lymphocyte proliferative response to antigen and IL7 stimulation by CDDO-TFEA and related triterpenoids.

Figure 4

CDDO-TFEA inhibits lymphocyte proliferation and modulates iNOS and Hmox-1 protein expression in the CNS of affected mice.

Triterpenoids have also been shown to control inflammation by suppressing expression of inducible nitric oxide synthase (iNOS) in macrophages. CNS levels of iNOS increase over the course of EAE³²^,33^,34^,35, resulting in prolonged exposure to nitric oxide³⁶ which is cytotoxic³⁷ and promotes inflammation³⁸. We found elevated levels of iNOS present in the lumbar spinal cord (Fig. 4B) and brain stem (Fig. 4C) of mice with EAE that were reduced significantly after CDDO-TFEA treatment. When the same tissues were evaluated for the expression of Hmox-1, we observed a reciprocal relationship. Prior reports have shown a link between hemin-induced Hmox-1 expression and reduced clinical severity of EAE in rats, whereas tin mesoporphyrin, a well-known inhibitor of Hmox-1 markedly exacerbated EAE¹⁵. Moreover, induction of EAE in Hmox1-/- mice led to enhanced CNS demyelination, paralysis, and mortality³⁹. The significant up-regulation of Hmox-1 protein in brain stem and lumbar spinal cord after CDDO-TFEA treatment suggests a possible mechanism through which this small molecule may be exerting neuroprotective effects in EAE.

Concomitant regulation of Nrf2-dependent and inflammatory gene transcription

The observed induction of Hmox-1 protein in CNS tissues following CDDO-TFEA exposure is consistent with the ability of the triterpenoids to activate Nrf2-dependent expression of the Hmox-1 gene. We used real-time PCR to evaluate the expression of Hmox-1 and several inflammation-related genes (including IFN-γ, IL-17 and iNOS) in total CNS tissue (Fig. 5A–B) and in splenocytes (Fig. 5C) and in mononuclear cells isolated from the CNS (Fig. 5D) of mice with EAE. A significant increase in Nrf2 and Hmox-1 transcripts was detected in lymphocytes of mice treated with CDDO-TFEA during the course of disease (Fig. 5A–C), and in mononuclear cells isolated from the CNS (Fig. 5D). Moreover, CDDO-TFEA significantly induced Nrf2 and Hmox-1 gene expression by encephalitogenic splenocytes cultured in the presence of MOG (35–55) (Fig. 5C).

Figure 5

CDDO-TFEA treatment modulates both antioxidant and inflammatory gene transcription in the CNS and in peripheral lymphocytes.

The pathogenic role of IL-17 in EAE has been substantiated by studies in mice deficient in IL-17 or the IL-17-inducing cytokine IL-23⁴⁰^,41. We observed complete suppression of IFN-γ and IL-17 gene expression in total CNS tissue (Fig. 5A–B) as well as in mononuclear cells isolated from brain stem and lumbar spinal cord (Fig. 5D) after CDDO-TFEA treatment. Moreover, CDDO-TFEA significantly reduced both IFN-γ and IL-17 expression by lymphocytes isolated from mice immunized with MOG (35–55), when these cells were re-exposed to MOG (35–55) in vitro (Fig. 5C). Collectively, these data highlight the multifunctional nature of the synthetic triterpenoids and the central role of Nrf2-mediated induction of pathways that combat oxidative stress, including the Hmox-1 pathway. The data also suggest the observed triterpenoid effect involves regulation of immune cells both at the site of disease and in the periphery.

CDDO-TFEA suppresses non-inflammatory LPC-induced demyelination

The data presented thus far suggests that neuronal integrity is maintained by CDDO-TFEA during EAE induction. However, the question remains whether this effect of CDDO-TFEA is solely due to immune suppression or whether triterpenoids also exert direct effects on myelin stability or regeneration. To address this question we utilized the well-established non-inflammatory lysophosphatidyl choline (LPC)-induced rodent model of myelin injury. Direct injection of LPC into neural tissue produces a localized vesicular demyelination of neurons that spares axons⁴². In the LPC-induced demyelination paradigm, a small amount of exogenous LPC injected into the dorsal columns of the thoracic spinal cord activates membrane bound phospholipase-A₂ which then hydrolyzes the lecithin of myelin leading to membrane solubilization and demyelination with fully developed lesions at 2 days post-injection⁴³. To test the efficacy of CDDO-TFEA on LPC-induced de-myelination, a total of 12 rats were subjected to LPC injection within dorsal column of spinal cord; 6 of these also received 10 nM CDDO-TFEA with LPC injection and then again at the site of injury 48 hours after LPC injection. Tissues were removed 7 days following injury and processed for immunostaining with anti-MBP antibody (for myelin), anti-GFAP antibody (for astrocytes) and anti-NG2 antibody (for oligodendrocytes).

Control mice (injected with PBS) exhibit intact myelin and a normal distribution of astrocytes (Fig. 6A–D) and oligodendrocytes (Fig. S5A–D). However, at the site of LPC injection neurons were completely demyelinated (Fig. 6G & Fig. S4G), astrocytes formed a glial scar around the demylinated area (Fig. 6F and 6H) and oligodendrocytes were recruited around demylinated axons (Fig. S5F and S5H). Myelin was significantly protected in the CDDO-TFEA treated group (Fig. 6K and Fig. S5K), with a comparatively normal distribution of astrocytes and oligodendrocytes. These data were further confirmed by toluidene blue staining and electron microscopy (Fig. 6M–R). We observed completely naked axons at the site of LPC injection (Fig. 6N & 6Q) while administration of CDDO-TFEA preserved myelin at the site of LPC injection (Fig. 6O and 6R), as defined by the percentage of myelinated axons and their G ratios in the dorsal horn of the spinal cord at the site of LPC injection (Fig. 6S–T).

Figure 6

CDDO-TFEA is neuroprotecive in the LPC-induced model of demyelination.

The data above indicate that CDDO-TFEA promotes preservation of myelin at the site of injury, but it is also possible that CDDO-TFEA may additionally promote myelin repair by facilitating oligodendrocyte maturation. To address this question, oligodendrocytes harvested from the CNS of day E18 rat embryos and were cultured for 10 days in either the presence or absence of CDDO-TFEA. CDDO-TFEA significantly enhanced maturation of oligodendrocyte precursors as shown by expression of maturation markers A2B5 (Fig. 7A–F & 7M) and O4 (Fig. 7G–L & 7N). These data indicate that during EAE, CDDO-TFEA and related synthetic triterpenoids act as multifunctional agents, both suppressing the immune response while also acting directly on neurons to protect them from the demyelination process and to promote myelin repair.

Figure 7

CDDO-TFEA induces early oligodendrocyte maturation.

A unique triterpenoid-modulated transcriptome underlies the resolution of EAE

To better characterize the triterpenoid modulated transcriptome in EAE we performed a gene microarray (Ilumina Sentrix array Ref. ^8v1.1) on lumbar spinal cord, directly comparing tissues collected from control mice and from mice following induction of EAE, with or without exposure to CDDO-TFEA. A total of 1433 genes were found to be differentially modulated in mice at the peak of EAE clinical scores compared to control mice (Fig. 8A). Among them, 135 genes known to be involved either in the cellular stress response or in inflammation were significantly altered by CDDO-TFEA treatment, and in most instances their expression returned to baseline (Fig. 8B–D). However, the induction of 11β-hydroxysteroid dehydrogenase type 1 (11bHSD1) and of prostaglandin D₂ synthase (PGDS) suggests that activation of steroid and prostaglandin biosynthetic pathways may contribute to the suppression of CNS inflammation by triterpenoids. We validated these gene array results by performing real time PCR on 9 different genes (Fig. 8E). The data suggest that inflammation driven suppression of both 11bHSD1 and of PGDS is reversed by exposure to CDDO-TFEA.

Figure 8

Microarray analysis of CNS tissues reveals global suppression of inflammatory genes by CDDO-TFEA in mice with EAE, with a concomitant induction of genes linked to resolution of inflammation.

Discussion

Multiple mechanisms operant in MS culminate ultimately in the generation of a highly oxidative microenvironment that is responsible for tissue injury and neurodegeneration⁴⁴^,45. The data presented here add to a growing body of literature that strongly support the clinical development of the family of natural and synthetic triterpenoids as chemopreventive and therapeutic agents in the context of neuro-inflammatory and neurodegenerative diseases, and specifically in the context of MS. While neuroprotective effects of administered exogenous antioxidants have been reported in EAE⁵^,46, pursuit of strategies that employ newer agents such as synthetic triterpenoids to induce endogenous enzymatic antioxidants should be a more efficient means to inhibit the detrimental effects of ROS and thereby serve as an effective form of chemoprevention for MS.

Synthetic oleanane triterpenoids have emerged as a potent class of pharmacologic agents capable of strongly inducing the Nrf2-ARE axis, and this mechanism has been identified as playing a principal role in the neuroprotective effects of CDDO derivatives in a variety of models of neurodegenerative disorders²⁷. For example, in the murine SOD-1 model of Amyotrophic Lateral Sclerosis (ALS)⁴⁷, exposure to CDDO-EA and CDDO-TFEA results in nuclear translocation of Nrf2 in cells expressing the SOD-1 mutant, and suppressed disease progression whether treatment was initiated in asymptomatic mice or at the onset of clinical manifestations. While the clinical response observed in the EAE model may be attributed to effects on Nrf2 expression and function, triterpenoids are multifunctional agents and it is quite likely that multiple targets participate in conferring protection in the setting of a complex neurodegenerative process like MS. For example, a role for Stat3 not only in the genesis of Th17 cells but also in the development of EAE has been defined⁴⁸^,49^,50. Our laboratory and others have shown that Stat3 is a direct target of the synthetic triterpenoids²⁸^,51. Our demonstration that triterpenoid exposure following induction of EAE significantly represses both IL-17 mRNA and protein expression suggests that this mechanism may also contribute to the overall clinical response to triterpenoids in the EAE model.

It is noteworthy that the link between an induction of Hmox-1 and repression of the development of a Th17 reponse has also been demonstrated for other activators of Hmox-1 in preclinical models of EAE and inflammatory bowel disease (IBD). Hemin, a potent inducer of Hmox-1 and activator of Nrf2⁵², suppresses the development of IBD in mice exposed to dextran sodium sulfate (DSS) and this effect is also associated with a significant reduction in the production of IL-17⁵³. Similarly, intraperitoneal administration of erythropoietin to MOG-EAE mice significantly reduced severity of disease in a manner that correlated with potent upregulation of Hmox-1 in the CNS and spleen and with a reduction of Th-17 T cell subsets⁵⁴. Finally, the observation that IL-17 might act to directly suppress the expression of Hmox-1 in the context of an inflammatory response argues that the balance between these two factors may in fact be an important determinant of disease expression. Thus the unique capacity of triterpenoids to simultaneously repress IL-17 expression through inhibition of Stat3 and to activate HO-1 through Nrf-2 suggests their utility for treatment of MS.

It is intriguing to find the induction of both 11β-hydroxysteroid dehydrogenase type 1 (11bHSD1) and of prostaglandin D₂ synthase (PGDS) in the CNS in mice exposed to CDDO-TFEA. It has been suggested that a local deficit of cortisol in the CNS may underlie the relapsing-remitting nature of MS, perhaps secondary to poor local activation of cortisone via 11β-hydroxysteroid dehydrogenase type 1 (11bHSD1)⁵⁵. MS patients have been found to maintain normal cortisol concentrations in serum yet exhibit lowered cortisol levels in the CSF during acute relapses. Although 11bHSD1 was not found to be expressed within active plaques, the significant induction in myelin-loaded macrophages in vitro suggests that production of this enzyme by infiltrating macrophages may contribute to the self-limiting nature of MS lesion development. Similarly, a reduction in the intrathecal synthesis of prostaglandin D₂ synthase (PGDS) has been documented during acute inflammatory demyelination⁵⁶, and enhanced biosynthesis of prostaglandin (PG)D₂ and subsequent formation of 15-deoxy-Δ-PGJ₂ has been implicated in the resolution of inflammation⁵⁷. It is intriguing that 15-PGJ₂ has been shown to activate Nrf2 signaling and to induce Hmox-1 in a manner similar to CDDO⁵⁸ thus demonstrating the capacity to contribute to the endogenous anti-oxidant response and raising the question whether the observed clinical response to triterpenoids shown here might reflect their capacity to mimic many of the functions of this endogenous anti-inflammatory protein.

Lastly, our data in the model of LPC-induced demyelination suggest that the efficacy of triterpenoids in the context of EAE is linked to a capacity to regulate astrocyte activation and to preserve CNS myelin. Nrf-2-/- mice develop a spontaneous progressive leukoencephalopathy, with vacuolar degeneration that is linked to myelin unwinding, intramyelinic cysts and oxidative damage to myelin¹⁰. Similarly, the observation that the anti-oxidant fumaric acid (FA) can preserve myelin and axonal density has also been linked to the capacity of FA and its esters to regulate Nrf-2 activity, and may be a mechanism contributing to the observed reduction of gadolinium enhancing lesions in MS patients treated with dimethylfumarate⁵⁹. Indeed, the beneficial effects of dimethylfumarate for axon preservation and astrocyte activation in the MOG-EAE model are lost in mice deficient in Nrf-2 gene expression⁶⁰.

In conclusion, the data present here demonstrate the efficacy of multifunctional triterpenoids in suppressing clinical and pathologic features of disease in preclinical models of MS. These small molecules have a unique capacity to simultaneously target intermediates that drive production of disease-inducing cytokines, such as IL-17, while inducing neuroprotective pathways activated through Nrf-2. Thus, synthetic triterpenoids may serve as both therapeutic and chemopreventive agents in the context of neurodegenerative and inflammatory diseases affecting the CNS.

Methods

Animals

C57BL/6 and SJL female mice (for EAE studies) and male Wistar rats (for LPC studies) were housed in a pathogen free animal facility in standard cages with free access to food and water in climate and light controlled rooms. All experimental procedures were approved by the Animal Care and Use Committee of the Case Western Reserve University.

EAE induction

EAE was induced in 10–12 weeks old, age matched female mice by subcutaneous immunization on both flanks with 200 μl of emulsion containing either Complete Fruend's adjuvant (100 μl of incomplete Fruend's adjuvant with 8 mg/ml of Mycobacterium Tuberculosis and 100 μl of PBS) (DIFCO Laboratories) or Complete Fruend's adjuvant with 200 μg of MOG (35–55). At the time of injection and 48 hours later 200 ng of pertussis toxin (List Biological Laboratories) was injected intrapertonially in 100 μl of PBS. Mice were monitored for daily clinical signs of EAE and the following criteria were used to grade clinical scores: 0-no signs of disease; 1-limp tail; 2-moderate hind-limb weakness; 3-severe hind-limb weakness; 4-Complete hind limb paralysis; 5- quadriplegia or premoribund state; 6-death.

Drug treatment

CDDO-Me, CDDO-EA or CDDO-TFEA were dissolved in a minimal amount of DMSO to obtain 10 mM stock and further dissolved in 7.5% PBST (7.5 ml Tween-80 dissolved in 100 ml of PBS) to obtain a final concentration of 100 nM. Animals were injected with 100 μl of this solution by intra-peritoneal (i.p.) injection at the interval of 48 hours for a total of 5 injections. Therapy was initiated in mice with varying severity of disease as noted by different clinical scores, starting after 15 days of MOG-35-55 immunization. Control animals were injected with a similar volume of vehicle i.e. 7.5% PBST.

Histology and immunohistochemistry

On day 18 to 23 (at clinical scores 4 to 5 in control mice with EAE) and at clinical score 0 in recipients of CDDO-TFEA treatment, mice were anesthetized and perfused with phosphate buffer saline (PBS) followed with 4% paraformaldehyde in PBS (PFA-PBS). Brain and spinal cord were collected and fixed in 4% PFA-PBS and embedded in paraffin to obtain 5 μm thick sections. At least 10 to 12 serial sections were obtained from 4 different regions of the brain (rostral cerebrum, mid cerebrum, mid brain and cerebellum with brain stem). Spinal cord was divided into 3 parts (cervical, thoracic and lumbar). At least 5 sections from each part and longitudinal serial sections of all regions were obtained for representation of the entire spinal cord. Tissue sections were stained with hematoxilin & eosin (H&E) to assess routine histology and inflammation and also with Luxol Fast Blue and the Periodic Acid Schiff reagent to analyze myelin content. Each section was assigned a histological score for inflammation and demylenation from 0 to 3 by an observer blinded to sample identity, where 0 represents no lesions, 1- moderate and 3 represents severe lesions. Spinal cord sections were immunostained with anti myloperoxidase antibody to detect granulocytes infiltration and anti-F4/80 antibody for macrophage and microglia.

Western blot analysis

Animals were sacrificed for tissue collection at different time points after immunization and drug treatment. Brain (further divided into forebrain, midbrain and hindbrain) and spinal cord (further divided into cervical, thoracic and lumbar) were collected and snap frozen. Tissue homogenates were prepared in lysis buffer, consisting of T-PER, tissue protein extraction reagent (Pierce, Rockford, IL), a protease inhibitor cocktail tablet (Roche, Mannheim, Germany) and 1 [ratio]

100 diluted phosphatase inhibitor mixtures I and II (Sigma, St. Louis, MO). Proteins were denatured and equal amounts of proteins were electrophoresed in 4–12% bis-Tris/polyacrylamide gels (NuPAGE; Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes with 0.2 μm pores (Invitrogen). The membranes were blocked for 2 h in blocking solution (TBS containing 10% nonfat dry milk and 0.05% Tween 20) and incubated overnight at 4°C with primary antibody diluted in blocking solution. Incubation with horseradish peroxidase-conjugated secondary antibody was performed at room temperature for 1 h, and immunoreactivity was detected by using enhanced chemiluminescence (Pierce, Rockford, IL).

Oligodendrocyte primary culture

Dissociated brain cultures were made from Sprague-Dawley rat pups at postnatal day 3, plated on poly-L-lysine/Laminin coated coverslips and grown in 1% fetal bovine serum in DMEM supplemented with GlutaMAX^TM, Penicillin-Streptomycin, Hong's N2 and PDGF-AA. Treatment with vehicle (control) or vehicle + 10 nM CDDO-TFEA began one day after dissociation and lasted for three, six or ten days in vitro. Immunocytochemical markers of the oligodendrocyte lineages were assayed, including A2B5 (for immature oligodendrocyte precursor cells), and O4, (for mature marker of oligodendrocyte precursor cells). A total of 100 to 300 total cells were counted from five different areas in each culture and positive immunoreactive cells for A2B5 or O4 were plotted as percentage of total cells.

Antibodies

The rabbit polyclonal anti-iNOS and anti-Hmox-1 (Santa Cruz Biotechnology,Santa Cruz, CA) were used for Western blot analysis (1 [ratio]

200). For immunohistochemistry 2μg/ml of rabbit polyclonal anti-myeloperoxidase (lot 373A603A (1); Lab Vision; Fremont, CA), or 10 μg/ml of the rat IgG2b MAb F4/80 (clone C1:A3-1; Serotec; Raleigh, NC) were used. Secondary horseradishperoxidase-conjugated antibodies were obtained from AmershamBiosciences (Piscataway, NJ) and used at 1 [ratio]

2000 dilution for immunoblots analysis and 2.5 μg/ml biotinylated rabbit anti-rat IgG secondary antibody (Vector Laboratories; Burlingame, CA) to detect F4/80 and 2.5 μg/ml biotinylated goat anti-rabbit IgG secondary antibody (Vector) to detect myeloperoxidase.

ELISA

Serum levels of IL-2, Il-4, IL-6, GM-CSF, TNF and IFN-γ were detected with OptiEIA Elisa sets (BD Biosciences and IL-17 was detected with DuoSet ELISA development System (R&D systems) as per manufacturer's suggested protocol.

Ex vivo restimulation of T cells

Mice immunized with or without MOG(35-55) (clinical score-5) or CDDO-TFEA treated (clinical score-0) were sacrificed and a single cell suspension was prepared from draining lymph nodes (Inguinal and brachial) and restimulated with 33 μg/ml of MOG (35–55) in presence or absence of CDDO-TFEA and 50 ng/ml mIL7. Cells were seeded in a 96 well plate at a density of 2×10⁵. After 72 hours culture supernatants were collected for analysis of cytokine secretion and cells were used for RNA preparation. For proliferation assays, 0.5 μci of (³H) thymidine was added in cultures during last 12 hours and thymidine incorporation was measured as cell proliferation.

LPC induced demyelination

Three to four months old male Wistar rats were used for this study. Demyelination in the spinal cord was induced by LPC injection as described previously³⁰ with subtle modification in protocol. In brief, animals were anesthetized with 5 ml per kg of body weight of 0.2 ml ketamine (Fort Dodge), 0.1 ml xylazine (Lloyd Laboratories) and 0.7 ml of distilled water. After shaving and cleaning with ethanol and betadine, a T10 laminectomy was performed in a stereotactic apparatus (Stoelting). Using a 30-mm glass micropipette attached to a Nano-injector (World Precision Instruments), 1.5 μl of 1% freshly prepared LPC (Sigma) solution was infused at 15 ml/hour. The needle was kept in place for 5 min to prevent reflux; the skin was closed and treated with Betagen (Med-Pharmex). In order to rule out any mechanical injury control rats were subjected to similar surgical process but in spite of LPC similar volume of PBS was injected. Rats received either 10 nM CDDO-TFEA or vechicle control at the time of LPC injection and again after 48 hours at the site of LPC injection. After 7 days all animals were sacrificed and targeted spinal cord tissue was collected and processed for electron microscopy (for analyzing the myelin content) and frozen tissue sections were used for immunostaing to analyze myelin content and recruitment of oligodendrocyte and glial cells at the site of injury.

Electron microscopy

We anesthetized and perfused the animals with Sorenson's buffer followed by solution containing 4% paraformaldehyde (wt/vol) and 2.5% glutararaldehyde (vol/vol). Spinal cords were sliced into 1–2-mm sections and post-fixed in the same solution overnight at 4°C, after which sections were embedded in Araldite resin. Semi-thin sections were stained with 1% Toluidine blue staining (wt/vol) at 65°C for a few seconds, washed several times with water and then dehydrated and mounted with Permount. Thin sections were cut, stained with uranyl acetate and lead citrate and analyzed. G ratios (defined as the diameter of the axon divided by the diameter of the axon and myelin) were calculated from the outer perimeter of the axon divided by the total perimeter of the axon and myelin. Six pictures were randomly chosen for each mouse and 100–200 fibers per picture were calculated. At least 6 mice per strain per time point were analyzed. The data are shown as G ratio and total number of myelinated fibers.

Oligonucleotide microarray analysis

Total RNA was isolated using Trizol reagent (Invitrogen) and RNeasy (Qiagen) from control and EAE mice lumbar spinal cord, treated with or without CDDO-TFEA. Each tissue sample was derived from a different individual mouse giving three true biological replicate samples. The yield was quantified using NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies, Delaware) and quality checked by conventional denaturing 1% agarose gel analysis. For microarray analysis, extracted total RNA was biotinylated and amplified using the Ilumina® TotalPrep RNA Amplification Kit. Labeled cRNA was then hybridized with IluminaSentrix® array (Sentrix Mouse Ref 8v1.1) according to their standard protocol (Illumina). Following hybridization and washing, arrays were scanned using IluminaBeadStudio (version 3.1). The raw data from all the arrays were then exported out and analyzed using GeneSpring 7.3.1 (Agilent Technologies). Expression of all genes on a chip was normalized globally to the expression value of the median of the chip and each gene normalized across conditions to a median of 1.0. This approach reduced the expression ratio for every gene in each of the control samples to 1 and set the expression ratio for each gene in each test sample to a value indicative of its expression relative to that in the corresponding control. The normalized data were then filtered by volcano plot to identify genes whose expression (in all three biological replicates) appears to be up- or down- regulated by an arbitrary cutoff of at least 1.5 fold with p-value = 0.05. Statistical analysis was performed on the log expression ratios utilizing one way Students t-test analysis of variance without any multiple testing correction. No post-hoc analysis was applied.

Quantitative Real-time polymerase chain reaction

10 µl of total RNA (2 micrograms) from each sample were reverse transcribed using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems) that contains 10X RT Buffer; 25X dNTP Mix (100 mM); 10RT Random Primers; Multiscribe^TM; Reverse Transcriptase and nuclease-free water in a final volume of 20 µl reaction mixture. Reverse transcription was performed using the following program on a thermal cycler (Applied Biosystems) using only 1 cycle: (step 1) at 25°C for 10 min; (step 2) at 37°C for 120 min; (step 3) at 85°C for 5 sec; and (step 4) at 4°C for infinity. QRT-PCR was performed with an ABI 7500 system (Applied Biosystems) to validate the microarray results on a number of genes apparently exhibiting differential expression. Pre-synthesized primers specific for the genes purchased from ABI are shown in Table 1.

Table 1

Quantitative PCR probes

Author Contributions

J.J.L. and T.K.P. conceived and coordinated the study, designed the experiments, analyzed the data and wrote the manuscript, T.K.P. carried out major biochemical and biological experiments, A.B carried out LPC studies, S.K. and S.L.L. performed and analyzed microarray experiments, A.Z. carried out OPC maturation experiments, L.B. helped with PLP-EAE experiments, M.L.C. performed histopathological analyses, C.M., K.T.L., R.H.M., M.B.S., T.K.P. and J.J.L. discussed the hypothesis and interpreted the data.

Supplementary Material

Supplementary Information

Supplementary Information

Click here to view.^{(3.8M, pdf)}

Acknowledgments

We are thankful to Janet Robinson and Jennifer Alabran for their expert technical support and helpful discussions. We also thank NUS, Singapore for providing travel support for Dr. Pareek. This work was supported by the intramural funds from CWRU and The Case Research Institute. Dr. Letterio would like to thank Jane and Lee Seidman for their support through their endowment for Pediatric Cancer Innovation.

Footnotes

A patent application (US 2009/0060873/A1) is pending related to use of synthetic triterpenoids in treatment of multiple sclerosis.

References

Noseworthy J. H., Lucchinetti C., Rodriguez M. & Weinshenker B. G. Multiple sclerosis. N Engl J Med 343, 938–952 (2000). [PubMed]
Gutcher I., et al. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity 34, 396–408 (2011). [PubMed]
Benveniste E. N. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev 9, 259–275 (1998). [PubMed]
Ruuls S. R., et al. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56, 207–217 (1995). [PubMed]
Gilgun-Sherki Y., Melamed E. & Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251, 261–268 (2004). [PubMed]
Smith K. J., Kapoor R. & Felts P. A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9, 69–92 (1999). [PubMed]
van Meeteren M. E., Teunissen C. E., Dijkstra C. D. & van Tol E. A. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 59, 1347–1361 (2005). [PubMed]
Johnson D. A., Amirahmadi S., Ward C., Fabry Z. & Johnson J. A. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci 114, 237–246 (2010). [PMC free article] [PubMed]
Innamorato N. G., et al. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181, 680–689 (2008). [PubMed]
Hubbs A. F., et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 170, 2068–2076 (2007). [PubMed]
Tajouri L., et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 119, 170–183 (2003). [PubMed]
Guy J., Qi X. & Hauswirth W. W. Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 95, 13847–13852 (1998). [PubMed]
Singh I., et al. Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res 1022, 1–11 (2004). [PubMed]
Liu Y., Liu J., Tetzlaff W., Paty D. W. & Cynader M. S. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic Biol Med 40, 960–967 (2006). [PubMed]
Liu Y., et al. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 12, 1841–1845 (2001). [PubMed]
Connolly J. D. & Hill R. A. Triterpenoids. Nat Prod Rep 18, 560–578 (2001). [PubMed]
Xu R., Fazio G. C. & Matsuda S. P. On the origins of triterpenoid skeletal diversity. Phytochemistry 65, 261–291 (2004). [PubMed]
Dzubak P., et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 23, 394–411 (2006). [PubMed]
Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 100, 92–94 (2005). [PubMed]
Raphael T. J. & Kuttan G. Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune system. Phytomedicine 10, 483–489 (2003). [PubMed]
Martin R., et al. Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role. Biochem Pharmacol 79, 198–208 (2010). [PubMed]
Tran T. A., McCoy M. K., Sporn M. B. & Tansey M. G. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation 5, 14 (2008). [PMC free article] [PubMed]
Pergola P. E., et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 33, 469–476 (2011). [PubMed]
Pergola P. E., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365, 327–336 (2011). [PubMed]
Dumont M., et al. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J Neurochem 109, 502–512 (2009). [PMC free article] [PubMed]
Liby K. T., Yore M. M. & Sporn M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7, 357–369 (2007). [PubMed]
Stack C., et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49, 147–158 (2010). [PMC free article] [PubMed]
Liby K., et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12, 4288–4293 (2006). [PubMed]
Yore M. M., Liby K. T., Honda T., Gribble G. W. & Sporn M. B. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 5, 3232–3239 (2006). [PubMed]
Bayer A. L., Lee J. Y., de la Barrera A., Surh C. D. & Malek T. R. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells. J Immunol 181, 225–234 (2008). [PMC free article] [PubMed]
Lundmark F., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39, 1108–1113 (2007). [PubMed]
Cross A. H., et al. Inducible nitric oxide synthase gene expression and enzyme activity correlate with disease activity in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 71, 145–153 (1996). [PubMed]
Koprowski H., et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A 90, 3024–3027 (1993). [PubMed]
Lin R. F., Lin T. S., Tilton R. G. & Cross A. H. Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study. J Exp Med 178, 643–648 (1993). [PMC free article] [PubMed]
Okuda Y., et al. Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J Neuroimmunol 62, 103–112 (1995). [PubMed]
Xie Q. & Nathan C. The high-output nitric oxide pathway: role and regulation. J Leukoc Biol 56, 576–582 (1994). [PubMed]
Henry Y., et al. Nitric oxide, a biological effector. Electron paramagnetic resonance detection of nitrosyl-iron-protein complexes in whole cells. Eur Biophys J 20, 1–15 (1991). [PubMed]
Ialenti A., Ianaro A., Moncada S. & Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 211, 177–182 (1992). [PubMed]
Chora A. A., et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest 117, 438–447 (2007). [PMC free article] [PubMed]
Chen Y., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116, 1317–1326 (2006). [PMC free article] [PubMed]
Hofstetter H. H., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237, 123–130 (2005). [PubMed]
Smith K. J. & McDonald W. I. Spontaneous and mechanically evoked activity due to central demyelinating lesion. Nature 286, 154–155 (1980). [PubMed]
Fuller M. L., et al. Bone morphogenetic proteins promote gliosis in demyelinating spinal cord lesions. Ann Neurol 62, 288–300 (2007). [PubMed]
Gonsette R. E. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult Scler 14, 22–34 (2008). [PubMed]
Witherick J., Wilkins A., Scolding N. & Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis 2011, 164608 (2010). [PMC free article] [PubMed]
van Meeteren M. E., Hendriks J. J., Dijkstra C. D. & van Tol E. A. Dietary compounds prevent oxidative damage and nitric oxide production by cells involved in demyelinating disease. Biochem Pharmacol 67, 967–975 (2004). [PubMed]
Neymotin A., et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 51, 88–96 (2011). [PMC free article] [PubMed]
Jadidi-Niaragh F. & Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 74, 1–13 (2011). [PubMed]
Jin W., Zhou X. F., Yu J., Cheng X. & Sun S. C. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 113, 6603–6610 (2009). [PubMed]
Ogura H., et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29, 628–636 (2008). [PubMed]
Ahmad R., Raina D., Meyer C. & Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 68, 2920–2926 (2008). [PMC free article] [PubMed]
Kim Y. C., et al. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J Biol Chem 276, 18399–18406 (2001). [PubMed]
Zhong W., et al. Hemin exerts multiple protective mechanisms and attenuates dextran sulfate sodium-induced colitis. J Pediatr Gastroenterol Nutr 50, 132–139 (2010). [PubMed]
Chen S. J., et al. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin Exp Immunol 162, 210–223 (2010). [PubMed]
Heidbrink C., et al. Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis. Brain Behav Immun 24, 975–984 (2010). [PubMed]
Huang Y. C., et al. Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 206, 100–105 (2009). [PubMed]
Rajakariar R., et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 104, 20979–20984 (2007). [PubMed]
Ikeda Y., et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J Biol Chem 275, 33142–33150 (2000). [PubMed]
Gold R., Linker R. A. & Stangel M. Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol (2011). [PubMed]
Linker R. A., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678–692 (2011). [PubMed]

Articles from Scientific Reports are provided here courtesy of
Nature Publishing Group